ENVALITH
新日本製薬株式会社 logo

Shinnihonseiyaku Co., Ltd.

4931Prime MarketChemicals

新日本製薬株式会社 logo
Shinnihonseiyaku Co., Ltd.4931
Reference Indicators

Market Cap

440¥100M

P/E (Forecast)

12.6x

P/B

1.9x

Dividend Yield (Forecast)

2.83%

ROE

11.5%

EV/EBITDA

5.0x
Financial Summary
Unit: ¥M
Item
2021Sep 2021
2022Sep 2022
2023Sep 2023
2024Sep 2024
2025Sep 2025
Net Sales
33,89936,10737,65340,04341,140
Cost of Sales
5,4396,7117,3418,2308,246
Gross Profit
28,46029,39530,31231,81232,894
SG&A Expenses
25,03225,87226,55727,63528,112
Operating Income
3,4243,5223,7544,1764,782
Non-operating Income
755645110138
Non-operating Expenses
85917818433
Ordinary Income
3,4143,4873,7214,1034,887
Extraordinary Income
360
Extraordinary Losses
1215191768
Pre-tax Income
3,4013,4743,5304,1104,118
Income Taxes
1,0831,1171,1351,3141,564
Net Income
2,3172,3572,3942,7952,554
EBITDA
3,8483,9504,1874,5665,147
Gross Margin
84.0%81.4%80.5%79.4%80.0%
Operating Margin
10.1%9.8%10.0%10.4%11.6%
ROA
10.0%9.9%9.4%10.3%9.0%
ROE
14.5%14.0%12.9%13.6%11.5%
Segment Performance
Unit: ¥M
2025
SegmentNet SalesOperating IncomeOperating Margin
通信販売000.0%
卸販売000.0%
海外販売000.0%
その他000.0%